Disability

Relievant Medsystems Announces More Than 10,000 Patients Treated with the Intracept® Procedure for Vertebrogenic Low Back Pain

MINNEAPOLIS, May 09, 2023 (GLOBE NEWSWIRE) -- Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic…

1 year ago

Pathways to Cures are in Sight as MS Canada Hosts Annual Day on the Hill with Carnation Pinning

OTTAWA, May 01, 2023 (GLOBE NEWSWIRE) -- Dozens of representatives of MS Canada are fanning across Ottawa May 1st – May…

1 year ago

TG Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

First quarter 2023 BRIUMVI net sales of $7.8 million Over 400 BRIUMVI prescriptions in the first partial quarter from 165+…

1 year ago

Clinical Study Shows 92% of Patients Report Resolution of Migraine Headaches Using Vivos’ POD® Appliance Treatment

Study Data Highlights New Vivos Treatment Option is Highly Effective in Treating Migraine Headaches, One of the World’s Most Common…

1 year ago

Praxis Precision Medicines to Present at the American Academy of Neurology 2023 Annual Meeting

BOSTON, April 19, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights…

1 year ago

IntelGenx Announces FDA Approval of RIZAFILM® for the Treatment of Acute Migraine

Partner Gensco® Pharma preparing to commercially launch RIZAFILM® across the United States as soon as is practicableSAINT LAURENT, Quebec, April…

1 year ago

CloudMD Names Dhruv Chandra Chief Technology Officer to Accelerate Technological Advancement in Next Phase of Growth

CloudMD strengthens its commitment to innovation, exceptional customer experiences, data-driven insights, security, and complianceVANCOUVER, British Columbia, April 10, 2023 (GLOBE…

1 year ago

The Hazelden Betty Ford Foundation and TELUS Health collaborate to expand substance use disorder treatment and mental health support

CENTER CITY, Minn. and VANCOUVER, British Columbia, April 05, 2023 (GLOBE NEWSWIRE) -- The Hazelden Betty Ford Foundation and TELUS…

1 year ago

Alterity Therapeutics Enrolls First Patient in the United Kingdom in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

MELBOURNE, Australia and SAN FRANCISCO, April 04, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the…

1 year ago